Lipocine (LPCN) Stock Forecast, Price & News

0 brokers have issued twelve-month target prices for Lipocine's stock. Their LPCN share price forecasts range from $68.00 to $68.00. On average, they predict the company's stock price to reach $68.00 in the next twelve months. This suggests a possible upside of 1,391.2% from the stock's current price.
View analysts price targets for LPCN or view top-rated stocks among Wall Street analysts.

Lipocine's stock was trading at $6.7626 at the start of the year. Since then, LPCN stock has decreased by 32.6% and is now trading at $4.56.
View the best growth stocks for 2023 here.

Lipocine saw a increase in short interest in May. As of May 15th, there was short interest totaling 80,100 shares, an increase of 32.0% from the April 30th total of 60,700 shares. Based on an average daily trading volume, of 26,100 shares, the days-to-cover ratio is presently 3.1 days. Approximately 1.6% of the company's stock are sold short.
View Lipocine's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our LPCN earnings forecast.

Lipocine Inc. (NASDAQ:LPCN) issued its quarterly earnings results on Friday, March, 10th. The specialty pharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter.

Shares of Lipocine reverse split before market open on Friday, May 12th 2023. The 1-17 reverse split was announced on Friday, May 12th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Lipocine investors own include Synergy Pharmaceuticals (SGYP), Flexion Therapeutics (FLXN), Trevena (TRVN), Heat Biologics (HTBX), Rigel Pharmaceuticals (RIGL), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Biocept (BIOC) and Catalyst Pharmaceuticals (CPRX).

Lipocine trades on the NASDAQ under the ticker symbol "LPCN."

Lipocine's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (1.66%), Wealth Effects LLC (0.85%), Two Sigma Investments LP (4.88%), Price T Rowe Associates Inc. MD (3.36%), Two Sigma Advisers LP (2.54%) and EP Wealth Advisors LLC (1.29%). Insiders that own company stock include John W Higuchi, Krista Fogarty, Mahesh V Patel, Morgan R Brown, Richard Dana Ono and Spyros Papapetropoulos.
View institutional ownership trends.

Shares of LPCN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of LPCN stock can currently be purchased for approximately $4.56.

Lipocine (NASDAQ:LPCN) has a market capitalization of $23.71 million and generates $500,000.00 in revenue each year. The specialty pharmaceutical company earns $-10,760,000.00 in net income (profit) each year or ($2.3809) on an earnings per share basis.

Lipocine's mailing address is 675 ARAPEEN DRIVE SUITE 202, SALT LAKE CITY X1, 84108. The official website for the company is www.lipocine.com. The specialty pharmaceutical company can be reached via phone at (801) 994-7383, via email at john.woolford@westwicke.co, or via fax at 801-994-7388.